VEGFA and Thromboembolism: The risk of cardiotoxicity in patients receiving VEGF inhibitors is 7.4% for hypertension, 1.8% for thromboembolism, 1.7% for cardiac ischemia, and 2.3% for general cardiac dysfunction.[4]